{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:55Z","timestamp":1786988035185,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejca.2024.115193","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T12:07:07Z","timestamp":1734437227000},"page":"115193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN \u2013 ALK fusion"],"prefix":"10.1016","volume":"216","author":[{"given":"Silvia","family":"Buriolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Zapelloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cipri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Pelizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Follador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cortiula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115193_bib1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00268-002-6612-1","article-title":"Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients","volume":"26","author":"Hay","year":"2002","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2024.115193_bib2","first-page":"4459","article-title":"Activated ras Oncogenes in Human Thyroid Cancers1","volume":"48","author":"Lemoine","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.115193_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","article-title":"BRAF mutation in papillary thyroid carcinoma","volume":"95","author":"Cohen","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.115193_bib4","first-page":"1454","article-title":"High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.115193_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the <em>ret<\/em> proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2024.115193_bib6","series-title":"Genes Environ. Cancer","first-page":"237","article-title":"Rearrangements of RET and NTRK1 Tyrosine Kinase Receptors in Papillary Thyroid Carcinomas","author":"Pierotti","year":"1998"},{"key":"10.1016\/j.ejca.2024.115193_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beem.2022.101656","article-title":"Genomic and epigenomic profile of thyroid cancer","volume":"37","author":"Acu\u00f1a-Ruiz","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2024.115193_bib8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1210\/en.2006-0921","article-title":"Minireview: RET\/PTC rearrangements and braf mutations in thyroid tumorigenesis","volume":"148","author":"Ciampi","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejca.2024.115193_bib9","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"Npj Precis Oncol"},{"key":"10.1016\/j.ejca.2024.115193_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0087170","article-title":"Identification of a recurrent STRN\/ALK fusion in thyroid carcinomas","volume":"9","author":"P\u00e9rot","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejca.2024.115193_bib11","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion asa potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2024.115193_bib12","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1089\/thy.2011.0511","article-title":"Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors","volume":"22","author":"Hamatani","year":"2012","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ejca.2024.115193_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jnci\/djx209","article-title":"Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer","volume":"110","author":"Efanov","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.115193_bib14","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.ajpath.2018.07.012","article-title":"Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion","volume":"188","author":"Nikitski","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2024.115193_bib15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated Genomic Characterization of Papillary Thyroid Carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2024.115193_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fonc.2022.1009076","article-title":"Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2024.115193_bib17","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","article-title":"Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma","volume":"33","author":"Godbert","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115193_bib18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/ajcp\/aqad169","article-title":"Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing","volume":"161","author":"Munoz-Zuluaga","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ejca.2024.115193_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cncy.22283","article-title":"High-risk and intermediate-high-risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution","volume":"128","author":"Jug","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.ejca.2024.115193_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115193_bib21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115193_bib22","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115193_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5306\/wjco.v11.i7.495","article-title":"Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: A case report and review of literature","volume":"11","author":"de Salins","year":"2020","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115193_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/thy.2019.0202","article-title":"Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib","volume":"30","author":"Leroy","year":"2020","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ejca.2024.115193_bib25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non\\&\\#x2013;Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2024.115193_bib26","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924018008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924018008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T20:16:16Z","timestamp":1738181776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924018008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"alternative-id":["S0959804924018008"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115193","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN \u2013 ALK fusion","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115193"}}